Physician experience and perceptions of tetrabenazine for the treatment of tardive dyskinesia and Huntington’s chorea: a survey of neurologists and psychiatrists
Although most physicians were moderately satisfied with TBZ, they also reported that TBZ side effects prevented reaching optimal clinical effectiveness and often led to discontinuation, suggesting a need for additional effective treatment options with favorable benefit-risk profiles for TD and HD-related chorea.
Authors
- Manho Kim (ORCID: https://orcid.org/0000-0002-0277-6326)
- Ayelet Yaari (ORCID: https://orcid.org/0000-0003-4782-8203)
- Tanya Gurevich (ORCID: https://orcid.org/0000-0003-2092-9848)
- Xavier Guillaume (ORCID: https://orcid.org/0009-0006-1882-3349)
- Perrine Le Calvé
- Anna S. Levin (ORCID: https://orcid.org/0000-0003-2427-8368)
- Daniel O. Claassen (ORCID: https://orcid.org/0000-0002-9853-4902)
- Victor Sung (ORCID: https://orcid.org/0000-0003-1024-3404)
- Rinat Ribalov
Institutions
- Oracle (United States) (US)
- Tel Aviv University (IL)
- New Generation University College (ET)
- Seoul National University Hospital (KR)
- University of Alabama at Birmingham (US)
- National University College (PR)
- Teva Pharmaceuticals (Czechia) (CZ)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Expert Review of Neurotherapeutics
- Published
- 2025-12-19
- DOI
- https://doi.org/10.1080/14737175.2025.2602188
- Primary Topic
- Genetic Neurodegenerative Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00